Exceptional revenue growth near 63% per year and three consecutive earnings beats demonstrate strong commercial momentum, but deeply negative free cash flow consuming roughly 89% of revenues, below-floor business quality, and a technical setup that has not yet confirmed a resumption of trend strength combine to limit the investable case despite the growth trajectory.
Thesis pillars
- Exceptional Revenue Growth Rate→Stable
- Improving Earnings Beat Cadence→Stable
- Severe Cash Burn Viability Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Jul 14, 2026
Kestra Medical Technologies, Lt (KMTS) Stock Analysis
Breakout setup
Healthcare · Medical Instruments & Supplies
Sell if holding. At $29.87, A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ASSURE WCD; Concentration risk — Customer: third-party payors Medicare, Medicaid and private payors.
Kestra Medical Technologies sells the ASSURE wearable cardioverter defibrillator, which monitors heart rhythm and delivers a shock for sudden cardiac arrest, as part of a digital Cardiac Recovery System. It earns nearly all revenue by leasing the device month-to-month and... Read more
Sell if holding. At $29.87, A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ASSURE WCD; Concentration risk — Customer: third-party payors Medicare, Medicaid and private payors. Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Score 5.1/10, moderate confidence.
Passes 6/8 gates (positive momentum, no SEC red flags, news events none recent, earnings proximity 46d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.
About Kestra Medical Technologies, Lt
About Kestra Medical Technologies, Lt
The ASSURE Wearable Cardioverter Defibrillator, which received FDA approval on July 27, 2021 and reached full commercial launch in August 2022, had protected nearly 40,000 patients as of April 30, 2026. Kestra Medical Technologies reported a net loss of $131.6 million for the fiscal year ended April 30, 2026, compared with $113.8 million a year earlier, and an accumulated deficit of $651.9 million. Global wearable defibrillator revenues reached approximately $1.1 billion in 2025, with over 80% coming from the United States, where the company currently sells exclusively.
Kestra generates revenue primarily by leasing the ASSURE device to patients for a fixed amount on a month-to-month basis and billing third-party payors, including Medicare, Medicaid and private payors. Medicare pays approximately $3,589 per month for months one to three under HCPCS code K0606, falling 25% to $2,692 for months four to thirteen, with a maximum of about $37,683 over a lease, and the company estimates it is in-network with payors covering over 290 million lives. A direct sales force of approximately 130 representatives targets cardiologists and electrophysiologists, supported by over 500 contracted Assure Patient Specialists who fit patients. Manufacturing is outsourced to third parties, and the company relies on a single or limited number of suppliers for certain components. Management says a post-approval study of 21,612 patients found only 6% experienced a false alarm, against 46% for the leading competitor's device as reported in a published study.
Show full overview
Reimbursement exposure and single-product dependence define the risk profile. The filing says nearly all revenue is billed to third-party payors and that revenues from the ASSURE device and associated services will continue to account for nearly all revenue for the foreseeable future, so a cut to Medicare or private rates, or shorter average wear times, may flow directly into results. The company has received no regulatory approvals outside the United States and targets European distribution within the next three years, while the filing says its primary competitor holds stronger relationships with healthcare providers and larger sales and marketing resources.
See also: Healthcare · Medical Instruments & Supplies
From Kestra Medical Technologies, Lt's most recent 10-K filing, extracted October 18, 2026.
Recent developments
updated 2026-10-29Recent Developments — Kestra Medical Technologies, Lt
Latest news
- NEWS Kestra Medical Technologies Appoints Daniel Finney as Vice President of Research & Development - Quiver Quantitative — Quiver Quantitative positive
- NEWS Kestra Medical Technologies Appoints Daniel Finney as Vice President of Research & Development - quiverquant.com — quiverquant.com positive
- NEWS KESTRA MEDICAL TECHNOLOGIES Q1 2027 Earnings Preview: Recent $KMTS Insider Trading, Hedge Fund Activity, and More - Quiv — Quiver Quantitative neutral
- NEWS KESTRA MEDICAL TECHNOLOGIES Q1 2027 Earnings Preview: Recent $KMTS Insider Trading, Hedge Fund Activity, and More - quiv — quiverquant.com neutral
- NEWS Kestra Medical Technologies (KMTS) Fiscal Q1 2027 Earnings Call: Revenue Up 60%, Guidance Raised - TradingKey — TradingKey positive
Generated 2026-10-29T11:08:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Concentration Risks(10-K Item 1A)
- HIGHProductASSURE WCD10-K Item 1A: 'We expect that revenues from our ASSURE WCD and associated products and services delivered as part of our Cardiac Recovery System platform will continue to account for nearly all of our revenue'
- HIGHCustomerthird-party payors Medicare, Medicaid and private payors10-K Item 1A: 'We derive nearly all our revenue from the direct billing of various third-party payors, including Medicare, Medicaid, private payors and other healthcare-related organizations'
- HIGHSuppliersingle or limited number of suppliers10-K Item 1: 'We rely on a single or limited number of suppliers for certain components of our ASSURE WCD.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $29.87, A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: ASSURE WCD; Concentration risk — Customer: third-party payors Medicare, Medicaid and private payors. Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Prior stop was $27.78. Score 5.1/10, moderate confidence.
Analyst target $26.75 reached (−10.4% from $29.87); no take-profit level is published. Prior stop was $27.78. Stop-loss: $27.78.
Concentration risk — Product: ASSURE WCD; Concentration risk — Customer: third-party payors Medicare, Medicaid and private payors; Analyst target reached - limited upside remaining.
Kestra Medical Technologies, Lt trades at a P/E of N/A (forward -14.5). TrendMatrix value score: 1.8/10. Verdict: Sell.
14 analysts cover KMTS with a consensus score of 4.3/5. Average price target: $31.
What does Kestra Medical Technologies, Lt do?Kestra Medical Technologies sells the ASSURE wearable cardioverter defibrillator, which monitors heart rhythm and...
Kestra Medical Technologies sells the ASSURE wearable cardioverter defibrillator, which monitors heart rhythm and delivers a shock for sudden cardiac arrest, as part of a digital Cardiac Recovery System. It earns nearly all revenue by leasing the device month-to-month and billing payors such as Medicare, Medicaid and private insurers. The device has protected nearly 40,000 patients, and the company reports a net loss of $131.6 million for fiscal 2026.